C4 Therapeutics Inc. Common Stock (CCCC)
Stock · NASDAQ · Health Care
$2.77as of 10/16/2026
Price chart
Active signals
CCCC Signal Track Record
How signals performed across all stocks →What CCCC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -1.1% | 45% | September 23, 2026 |
| Bollinger Band Breakdown | 22 | -6.5% | 41% | September 8, 2026 |
| Bollinger Band Breakout | 21 | -6.7% | 29% | August 12, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -2.9% | 40% | September 23, 2026 |
| Any 20-session window (baseline) | -2.9% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 104
- Website
- c4therapeutics.com/
Fundamentals
- 1-day range
- $2.7$2.81
- Market cap
- $402.46M
- P/E (trailing)
- —
- P/E (forward)
- -2.87
- EPS (trailing)
- $-1.00
- Dividend yield
- —
- Beta
- 3.15
- Avg. volume
- 2.35M
How C4 Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
C4 Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CCCCC4 Therapeutics Inc. Common Stock$2.77▼ 0.54%Market cap $402.46MP/E —$1.69$5.17
- STROSutro Biopharma Inc. Common Stock$10.94▼ 4.54%Market cap $400.18MP/E —$7.15$43.85
- XFORX4 Pharmaceuticals Inc. Common Stock$2.59▼ 1.89%Market cap $393.31MP/E 3.24$2.43$4.83
- OCGNOcugen Inc. Common Stock$0.78▼ 4.18%Market cap $420.50MP/E —$0.785$2.73
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
- PALIPalisade Bio Inc. Common Stock$1.41▼ 8.44%Market cap $362.78MP/E —$1.32$2.86
- CMPXCompass Therapeutics Inc. Common Stock$0.86▼ 4.12%Market cap $358.37MP/E —$0.8294$6.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CCCC C4 Therapeutics Inc. Common Stock | $402.46M | — | $2.77 | ▼ 0.54% | $1.69$5.17 |
| STRO Sutro Biopharma Inc. Common Stock | $400.18M | — | $10.94 | ▼ 4.54% | $7.15$43.85 |
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $2.59 | ▼ 1.89% | $2.43$4.83 |
| OCGN Ocugen Inc. Common Stock | $420.50M | — | $0.78 | ▼ 4.18% | $0.785$2.73 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $1.41 | ▼ 8.44% | $1.32$2.86 |
| CMPX Compass Therapeutics Inc. Common Stock | $358.37M | — | $0.86 | ▼ 4.12% | $0.8294$6.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10benzinga · 10/9/2026
- JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10Benzinga · 10/9/2026
- Gapping stocks in Friday's sessionChartMill · 10/9/2026
- Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?Yahoo · 10/9/2026
- PepsiCo, Delta Lead Upcoming Earnings Slate; Fed Minutes In FocusSeekingAlpha · 10/3/2026
- C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual MeetingYahoo · 9/25/2026
- C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual MeetingBenzinga · 9/25/2026
- Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?Yahoo · 9/23/2026
Insider Activity
Insider Actions →- Kenneth Carl Anderson · October 1, 2026 · Grant3.7K @ $3.14
- Donna Roy Grogan · October 1, 2026 · Grant4.6K @ $3.14
- Kendra Adams · September 18, 2026 · Tax Withholding2.8K @ $3.39
- Kendra Adams · September 18, 2026 · Option Exercise6.3K
- Leonard Reyno · July 10, 2026 · Tax Withholding7.4K @ $4.06
- Leonard Reyno · July 10, 2026 · Option Exercise15.3K
- Donna Roy Grogan · July 1, 2026 · Grant3.3K @ $4.34
- Kenneth Carl Anderson · July 1, 2026 · Grant2.6K @ $4.34
- Koppikar Utpal · June 24, 2026 · Grant62.0K
- Kenneth Carl Anderson · June 24, 2026 · Grant62.0K
- Ronald Harold Wilfred Cooper · June 24, 2026 · Grant62.0K
- Bessen Laura · June 24, 2026 · Grant62.0K
- Fawell Stephen · June 24, 2026 · Grant62.0K
- Donna Roy Grogan · June 24, 2026 · Grant62.0K
- Hughes Owen · June 24, 2026 · Grant62.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 80.99M
- Total value held
- $207.41M
- Institutional holders
- 119
- Unknown9.07M
- Unknown8.00M
- Unknown7.17M
- Unknown7.00M
- Unknown3.86M
- Unknown3.80M
- Unknown3.04M
- Unknown2.96M
- Unknown2.59M
- Unknown2.46M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.